VIA
JANX icon

Vident Investment Advisory’s Janux Therapeutics JANX Stock Holding History

Vident Investment Advisory’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-55,483
Closed -$671K – 1266
2023
Q1 		$671K Sell
55,483
-2,031
-4% -$33.8K 0.02% 669
2022
Q4 		$757K Buy
+57,514
New +$842K 0.03% 562

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vident Investment Advisory's JANX Position: Q2 2023 in Review

Vident Investment Advisory sold out of Janux Therapeutics (JANX) in Q2 2023, closing a stake of 55,483 shares — an estimated $671K sold.

Vident Investment Advisory first reported a position in JANX in Q4 2022 and held it in 2 quarters. The position peaked at $757K in Q4 2022. 54 funds tracked by Wall St. Rank hold JANX as of Q2 2023.

  • Vident Investment Advisory reported no remaining Janux Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Vident Investment Advisory sold 55,483 Janux Therapeutics shares in Q2 2023, an estimated $671K.
  • Vident Investment Advisory first reported a position in Janux Therapeutics in Q4 2022 and held it in 2 quarters.
  • Vident Investment Advisory's Janux Therapeutics position peaked at $757K in Q4 2022.
  • 54 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2023.

Based on Vident Investment Advisory's 13F filing for Q2 2023, filed 11 Aug 2023.